Johnny joined Omega Funds in 2018, where he focuses on private company investing, with a focus on new therapeutic modalities. He is especially interested in gene and cell therapies due to his previous work in the space. Prior to Omega, Johnny completed his PhD at Harvard University as a National Defense Science and Engineering Graduate Fellow and National Science Foundation Graduate Research Fellow in the labs of David Liu and George Church. His thesis project focused on using directed evolution to evolve new gene editing tools and was published in Nature. Previously, he also interned with Vida Ventures, PureTech Health, RA Capital, and Genentech. Johnny earned his MPhil as a Gates Cambridge Scholar from the University of Cambridge and his AB summa cum laude in Chemical and Physical Biology from Harvard University.